A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when
used by itself or together with another medicine called Bacillus Calmette Guerin (BCG),
and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder c...
Age: 18 years - 66+
Gender: All
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT
followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the
treatment of participants with IR-NMIBC.
Age: 18 years - 66+
Gender: All
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC)
patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a
non-inferior event-free survival (EFS) compared to standard treatment with intravesical
BCG. The pu...
Age: 18 years - 66+
Gender: All
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC)
patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a
non-inferior event-free survival (EFS) compared to standard treatment with intravesical
BCG. The pu...
Age: 18 years - 66+
Gender: All